AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 OCT 10 - (NewsRx.com & NewsRx.net) --
CEL-SCI Corporation presented a poster at the AIDS Vaccine 2001 Congress held in Philadelphia, Pennsylvania entitled "C Clade HGP-30 (p17 aa 86-115) Based Peptide Conjugates as Potential Therapeutic and Prophylactic HIV-1 Vaccine Antigens."
In it, strong evidence of cellular immune responses and recognition of different strains of the AIDS virus was reported. The immunotherapeutic agent (L.E.A.P.S. conjugate) combines a peptide sequence representing a region of the HIV-1 core protein, p17, with a peptide designed to induce a cellular immune response against the HIV peptide.
The evaluation of the L.E.A.P.S. conjugates was conducted in mice and the antibody responses induced by vaccination were assessed for their abilities to bind to peptide sequences representing the major clades (strains) of HIV found worldwide, A, B, C, D, and E. It was found that one of the conjugates, which included the C clade sequence of HGP-30, induced antibodies which showed significant cross clade recognition. Significant titers of immunoglobulin G (IgG)2a subtype antibodies, an antibody associated with the induction of cellular TH1 immune responses, were also observed with this same conjugate.
Dr. Dan Zimmerman, of CEL-SCI, and inventor of the technology said, "We have combined our L.E.A.P.S. and HGP-30 technologies to design a potential vaccine antigen which we believe targets specific types of immune cells and elicits the most appropriate responses against HIV-1. The goal of this work is to develop a prototype formulation which will be cheap to make and easy to administer. Such a ...